Intellijoint Surgical, Inc. will have its coffers full enough to expand as they wish over the coming months. The company, which focuses on 3D mini-optical navigation, has just completed a round of Series A financing—a whopping $11 million. According to the November 1, 2016 news release, “The Series A was led by private investors from the Waterloo-Toronto corridor and closed in multiple tranches.”
$11MM to Intellijoint Surgical!
2 min read Premium comments
Secondary
“The US launch of the next generation intellijoint HIP earlier this year is being extremely well received in the marketplace and is seeing significant growth, ” commented Intellijoint Surgical CEO and Co-Founder Armen Bakirtzian. “This Series A capital will allow Intellijoint to enhance its product offering with the Direct Anterior Approach Application and allow for expansion into new US markets while enabling deeper penetration of Intellijoint’s presence in New York and Illinois.”
“Intellijoint has addressed the shortcoming of traditional navigation. The miniature optical camera provides accurate measurements while compensating for patient movement, which is routine during a total hip replacement. It provides me with valuable information and I choose to use it in every case, ” added Wayne Paprosky, M.D., Midwest Orthopaedics at Rush and member of Intellijoint’s scientific medical advisory board.
Dr. Paprosky told OTW, “intellijoint HIP displays real-time, intraoperative measurements allowing me to fine tune leg length, offset and cup position to meet preoperative targets. The registration is streamlined compared to other technologies, adding minimal time to my procedure. I can confidently remove outliers that all surgeons can experience in our practices.”
The company provided OTW with the following case description:
During a total hip replacement at a large non-profit health care system in New York, intellijoint HIP was used to assist in restoring mobility in a patient who was unusually young for total hip arthroplasty.
This young patient suffered from sickle cell anemia causing insufficient blood supply to the left hip. The patient developed avascular necrosis. The bone had begun to crack and collapse, therefore, significantly shortening the patient’s left leg.
This young patient came into surgery with nearly a 20-millimeter leg length discrepancy.
With intellijoint HIP providing real-time, intraoperative measurements for cup position, leg length and offset, the patient’s surgeon confidently selected the correct sized implants. The surgeon restored the patient’s hip while lengthening the left leg by 18 millimeters to match the right leg length. Intellijoint HIP assisted in reaching pre-operative targets that post-operatively improved the patient’s quality of life through increased mobility.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.